TRACON Pharmaceuticals, Inc. (TCON) Files An 8-K Other Events
Item 8.01Other Events.
On November 11, 2016, TRACON Pharmaceuticals, Inc. (TRACON)
issued a press release announcing updated results from the
on-going Phase 1b/2 clinical trial of TRC105 in combination with
Votrient (pazopanib) in soft tissue sarcoma.The press release
issued on November 11, 2016 is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
On November 13, 2016, TRACON issued a press release announcing
preclinical data from two separate liver fibrosis models in a
poster presentation entitled Endoglin Antibody Reduces the NAFLD
Activity Score in the STAM Model of NASH and Reduces Liver
Fibrosis Following Carbon Tetrachloride Treatment. The press
release issued on November 13, 2016 is attached hereto as Exhibit
99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release issued by TRACON Pharmaceuticals, Inc. |
|
99.2 |
Press release issued by TRACON Pharmaceuticals, Inc. |
About TRACON Pharmaceuticals, Inc. (TCON)